European Federation of Pharmaceutical Industry Associations

What European Federation of Pharmaceutical Industry Associations does

EFPIA (European Federation of Pharmaceutical Industries and Associations), founded in 1978 and headquartered in Brussels with Luxembourg incorporation, is the trade federation representing research-based pharmaceutical companies operating in Europe. Its core function is policy advocacy and industry coordination: it engages directly with EU institutions (European Commission DG SANTE, European Parliament SANT Committee, Council of the EU) on pharmaceutical legislation, the EU Biotech Act, the EU HTA Regulation, trade policy, and access to medicines. Its members consist of approximately 36 national pharmaceutical industry associations across Europe plus direct member companies, organized through specialized groups such as Vaccines Europe and the European Biopharmaceutical Enterprises (EBE).

EFPIA's "products" are policy publications and multi-stakeholder initiatives rather than commercial goods. The portfolio includes the WAIT Indicator (annual access analysis across 36 countries for 168 medicines), the Cancer Comparator Report 2025, the Competitiveness Ecosystem Report, the EFPIA Code of Practice governing HCP and patient-organization relationships, and disease-specific platforms such as the EFPIA Oncology Platform (22 companies) and the Alzheimer's Disease Platform. It co-leads the Innovative Health Initiative (IHI), the world's largest life-sciences public-private partnership, with active projects spanning antimicrobial resistance, cardiovascular disease, AI-driven drug discovery, big-data harmonization, and regulatory sandboxes.

EFPIA is funded by membership fees from national associations and direct member companies, with governance led by Director General Nathalie Moll and President Stefan Oelrich (also President of Pharmaceuticals at Bayer AG). It operates with 11-50 staff, runs a content-and-events marketing motion (newsletter, EFPIA View blog, policy conferences, social media), and explicitly positions its value as the unified voice of Europe's research-based pharmaceutical industry. EFPIA is not a commercial enterprise and does not generate revenue from product sales; its economic significance lies in representing an industry that invests EUR 55 billion annually in EU R&D, supports 2.3 million jobs, and generates EUR 366 billion in exports.

Name

European Federation of Pharmaceutical Industry Associations

Legal name

European Federation of Pharmaceutical Industries and Associations (EFPIA)

Website

https://efpia.eu

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

11–50 employees

Short description

EFPIA is the Brussels-based trade federation, founded in 1978, representing Europe's research-based pharmaceutical industry through policy advocacy, member coordination across ~36 national associations, and major publications (WAIT Indicator, Cancer Comparator Report, Competitiveness Ecosystem Report). It leads the IHI public-private partnership and administers the EFPIA Code of Practice.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Trade Association

NAICS

Business Associations (813910), Professional Organizations (813920)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Pharmaceutical industry association
• Policy advocacy services
• Regulatory affairs consulting
• Industry research publications
• Trade federation membership

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership fees: EFPIA is funded by membership fees from national pharmaceutical industry associations and direct member companies across Europe. The federation coordinates industry positions, publishes research, and advocates on behalf of its members on regulatory, trade, pricing, and access policy matters.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

The European Federation of Pharmaceutical Industry Associations (EFPIA) is a trade federation representing the research-based pharmaceutical industry operating in Europe. It coordinates member positions on EU pharmaceutical policy, regulation, and legislation; conducts advocacy toward EU institutions; produces industry research and data publications; and administers self-regulatory codes governing industry practices.

Product overview

EFPIA is a federation representing the European pharmaceutical industry, providing policy advocacy, research publications, and multi-stakeholder initiatives rather than commercial products. Its portfolio includes research reports (Cancer Comparator Report, W.A.I.T. Indicator, Competitiveness Ecosystem Analysis), regulatory frameworks (EFPIA Code of Practice), disease-specific platforms (Oncology Platform, Alzheimer's Disease Platform), and participation in IHI public-private partnership research projects focused on cardiovascular disease, osteoarthritis, AI-driven drug discovery, antimicrobial resistance, and regulatory innovation. These offerings serve the pharmaceutical ecosystem through knowledge sharing, policy influence, and collaborative research rather than commercial product delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• EFPIA Patients W.A.I.T. Indicator

Quantifiable outcome

• Pharmaceutical companies invest €55 billion annually in EU R&D, supporting 2.3 million jobs and generating €366 billion in exports
• +4 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

20 partnerships are on record, tiered core and minor.

• IHI (Innovative Health Initiative)coreStrategic or Co-development PartnerIHI is the world's largest public-private partnership in life sciences, building on the IMI programme launched in 2008. It translates health research into patient benefits by combining EU funding with industry contributions including scientific expertise, regulatory knowledge, unique data, compounds, and research infrastructure. IHI projects address AMR, AI, big data, regulatory innovation, and cardiovascular disease.
• Vaccines EuropecoreStrategic or Co-development PartnerVaccines Europe is the specialised vaccine industry group within EFPIA, representing major innovative research-based global vaccine companies as well as SMEs operating in Europe. It operates as a dedicated division of EFPIA focusing on vaccine-specific policy, access, and regulatory matters.
• European Biopharmaceutical Enterprises (EBE)coreStrategic or Co-development PartnerEBE represents the voice of biopharmaceutical companies of all sizes in Europe. Established in 2000, it is recognised as the leading biopharmaceutical association in Europe and operates as a specialised group within EFPIA.
• EMVO (European Medicines Verification Organisation)minorStrategic or Co-development PartnerEMVO supports the Falsified Medicines Directive through the European Medicines Verification System. EFPIA participates in or supports this initiative.
• ICH (International Council for Harmonisation)coreStrategic or Co-development PartnerICH brings together regulatory authorities and pharmaceutical industry representatives to develop harmonised technical guidelines and standards for pharmaceutical product registration, ensuring alignment across global markets.
• DIA (Drug Information Association)coreGTM or Marketing PartnerDIA collaborates with EFPIA on events including the Global QPPV Forum, Excellence in Pharmacovigilance training, and other professional development programmes for pharmacovigilance professionals across Europe.
• EFGCP (European Forum for Good Clinical Practice)minorGTM or Marketing PartnerEFGCP organises the Better Medicines for Children Conference, which EFPIA supports as a partner event covering innovations in paediatric medicine development.
• Dutch Medicines Evaluation Board (MEB)minorStrategic or Co-development PartnerThe MEB collaborates with DIA and EFPIA on the Excellence in Pharmacovigilance training course covering GVP Modules I to XVI, delivered face-to-face in Amsterdam.
• Cities@Heart (IHI project)minorStrategic or Co-development PartnerIHI project on the role of Europe's cities in combating cardiovascular disease. Works across seven cities: Belfast, Birmingham, Cork, Izmir, Łódź, Udine, and Utrecht. Budget of over €28.5 million (€15.2m EU funding, €13.4m industry). EFPIA members contribute expertise and resources alongside public partners.
• BRIDGE (IHI project)minorStrategic or Co-development PartnerIHI project developing recommendations for regulatory sandboxes — flexible spaces where innovators and regulators explore how to regulate new technologies. Supported by EU funding of €5.2 million and industry contributions of €4.3 million.
• UNIFIED (IHI project)minorStrategic or Co-development PartnerIHI project integrating patient voices into clinical decision-making through a unified framework for patient-reported outcomes across clinical development, regulatory review, HTA, reimbursement, and clinical practice. €12.6m EU funding, €9.7m industry, €3.9m contributing partners.
• PROBE (IHI project)minorStrategic or Co-development PartnerIHI project using big data and AI/machine learning to advance knee osteoarthritis care, harmonising datasets from across Europe. €14m EU funding, €13.2m industry, €4.3m contributing partners.
• LIGAND-AI (IHI project)minorStrategic or Co-development PartnerIHI project using AI to accelerate drug discovery by modelling how molecules bind to proteins. Screens over 2,000 proteins against billions of molecules. €29.9m EU funding, €30.2m industry, €2.5m contributing partners.
• GUIDE-AI (IHI project)minorStrategic or Co-development PartnerIHI project building AI-powered 'guideline navigators' that help clinicians follow expert guidelines for chronic diseases (heart failure, CKD, COPD, asthma) using large language models. €4.9m EU funding, €4.2m industry.
• END2AMR (IHI project)coreStrategic or Co-development PartnerIHI project tackling antimicrobial resistance (AMR) by reinvigorating development of treatments for drug-resistant infections including tuberculosis, invasive bacterial diseases, and wound infections. Around €15 million each from EU and industry.
• Cyprus Ministry of HealthminorGTM or Marketing PartnerCo-host of the Unlocking Europe's Life Science Potential event in Nicosia, Cyprus on 8 May 2026, bringing together policymakers, industry leaders, researchers and patient representatives.
• European Commission DG SANTEcoreGTM or Marketing PartnerEFPIA engages with the European Commission's Directorate-General for Health and Food Safety on pharmaceutical legislation, the EU Biotech Act, Life Sciences Strategy, Strategic Dialogue on Pharmaceuticals, and joint clinical assessments under the EU HTA Regulation.
• European Parliament SANT CommitteecoreGTM or Marketing PartnerEFPIA engages with the European Parliament's Committee on Health (SANT) on pharmaceutical policy, access to medicines, and competitiveness legislation.
• European Parliament and Member States (EU HTA Regulation)coreStrategic or Co-development PartnerEFPIA welcomed the publication of the first Joint Clinical Assessment (JCA) report under the EU HTA Regulation, resulting from 14 months of joint work involving Member States, the European Commission, and industry stakeholders to streamline health technology assessment across the EU.
• Vaccines EuropecoreStrategic or Co-development PartnerVaccines Europe joined EFPIA in welcoming the European Commission's Global Health Resilience Initiative Communication, emphasising the importance of prevention, vaccination, resilient supply chains, and voluntary partnerships for global health resilience.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pharmaceutical Research and Manufacturers of America (PhRMA): The principal US pharmaceutical industry trade association representing research-based pharma companies. Directly comparable to EFPIA as the Western Hemisphere counterpart, with the same advocacy mission on legislation, IP, pricing, and access — the main geographic substitute for EFPIA in global pharma policy.
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Geneva-based global umbrella federation of pharma industry associations. Directly comparable to EFPIA as the global parent federation, coordinating with EFPIA on WHO, ICH, and trade-policy engagement; effectively EFPIA's superset at the global level.
• Association of the British Pharmaceutical Industry (ABPI): UK pharmaceutical industry trade association with parallel code-of-practice, disclosure, and policy-advocacy functions. Comparable to EFPIA in operating model and mandate, focused on the UK regulatory and NICE environment.
• Japan Pharmaceutical Manufacturers Association (JPMA): Japan's primary pharma industry trade association, cited in EFPIA's expanded competitiveness benchmarking (JP inclusion in the 2026 update). Comparable as the Asia-Pacific counterpart federation with parallel roles on regulation, pricing, and international harmonization.
• Biotechnology Innovation Organization (BIO): US-based biotech industry trade association. Comparable to EFPIA's advocacy and public-private partnership workstream, but with a stronger biotech/SME focus; a natural counterpart on EU Biotech Act and SME-related policy areas EFPIA has prioritized.
• Medicines for Europe: European generic and value-added medicines industry association, headquartered in Brussels. Directly comparable as the generic-side counterpart to EFPIA in EU regulatory, pricing, and access debates; an adjacent federation working the same Brussels ecosystem.
• European Confederation of Pharmaceutical Entrepreneurs (EUCOPE): Brussels-based association representing small and mid-sized European pharma and biotech companies. Comparable as a Brussels-based pharma policy advocate focused on SME-tailored issues EFPIA has prioritized (SMEs in Europe).

Regional players

• Association of the European Self-Care Industry (AESGP): European self-care / OTC medicines trade association based in Brussels. Comparable as a regional industry federation operating in the same Brussels policy environment for adjacent (consumer-health) products.
• German Association of Research-Based Pharmaceutical Companies (vfa): Germany's leading research-based pharma industry association. Comparable as a national counterpart federation (similar mandate on regulation, innovation, IP), operating as a key national member within the EFPIA network.

Others

• Innovative Health Initiative (IHI): Public-private partnership between the EU and pharma industry, including EFPIA members. Directly comparable and closely related: EFPIA operates as the industry-coordination arm within IHI governance and contributes resources/scientific input.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/efpia
• LinkedInlinkedin.com/company/efpia

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Federation of Pharmaceutical Industry Associations